Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

G. Tafuri · SciRah

Researcher profile · Semantic Scholar

G. Tafuri

Share profile

G. Tafuri — researcher profile on SciRah

h-index: 15
Works: 36
Citations: 784

Most-cited papers

Current state of quality of life and patient-reported outcomes research.
A. Bottomley, J. Reijneveld, M. Koller, H. Flechtner +29 more
2019European Journal of Cancer139 citations Open access
Semantic Scholar
Fish oil and mental health: the role of n-3 long-chain polyunsaturated fatty acids in cognitive development and neurological disorders
A. Assisi, R. Banzi, Carmela Buonocore, F. Capasso +7 more
2006International Clinical Psychopharmacology104 citations
Semantic Scholar
Evaluation of oncology drugs at the European Medicines Agency and US Food and Drug Administration: when differences have an impact on clinical practice.
F. Trotta, H. Leufkens, J. Schellens, R. Laing +1 more
2011Journal of Clinical Oncology72 citations
Semantic Scholar
How aligned are the perspectives of EU regulators and HTA bodies? A comparative analysis of regulatory‐HTA parallel scientific advice
G. Tafuri, M. Pagnini, Jane Moseley, M. Massari +12 more
2016British Journal of Clinical Pharmacology61 citations Open access
Semantic Scholar
Managing Risk and Uncertainty in Health Technology Introduction: The Role of Managed Entry Agreements
P. Kanavos, A. Ferrario, G. Tafuri, P. Siviero
201759 citations Open access
Semantic Scholar
How do the EMA and FDA decide which anticancer drugs make it to the market? A comparative qualitative study on decision makers' views.
G. Tafuri, Pieter Stolk, Francesco Trotta, Michelle Putzeist +3 more
2014Annals of Oncology48 citations Open access
Semantic Scholar
Determinants of price negotiations for new drugs. The experience of the Italian Medicines Agency.
F. Villa, M. Tutone, G. Altamura, S. Antignani +6 more
2019Health Policy45 citations
Semantic Scholar
In reply to: Knowledge of developmental pharmacology and modeling approaches should be used to avoid useless trials in children
G. Tafuri, F. Trotta, H. Leufkens, N. Martini +2 more
2009European Journal of Clinical Pharmacology45 citations Open access
Semantic Scholar
The impact of parallel regulatory–health technology assessment scientific advice on clinical development. Assessing the uptake of regulatory and health technology assessment recommendations
G. Tafuri, Inês Lucas, S. Estevão, Jane Moseley +18 more
2018British Journal of Clinical Pharmacology34 citations Open access
Semantic Scholar
Stopping a trial early in oncology: for patients or for industry?
Francesco Trotta, G. Apolone, S. Garattini, G. Tafuri
2008Annals of Oncology23 citations Open access
Semantic Scholar
Using GRADE methodology to assess innovation of new medicinal products in Italy
F. Fortinguerra, G. Tafuri, Francesco Trotta, A. Addis
2020British Journal of Clinical Pharmacology20 citations Open access
Semantic Scholar
Disclosure of grounds of European withdrawn and refused applications: a step forward on regulatory transparency.
G. Tafuri, F. Trotta, H. Leufkens, L. Pani
2013British Journal of Clinical Pharmacology20 citations Open access
Semantic Scholar
Haematological anticancer drugs in Europe: any added value at the time of approval?
V. Bertele', R. Banzi, F. Capasso, G. Tafuri +3 more
2007European Journal of Clinical Pharmacology19 citations
Semantic Scholar
Orphan Drug Prices and Epidemiology of Rare Diseases: A Cross-Sectional Study in Italy in the Years 2014–2019
F. Villa, Aurora Di Filippo, A. Pierantozzi, A. Genazzani +6 more
2022Frontiers in Medicine17 citations Open access
Semantic Scholar
Assessment of significant benefit for orphan medicinal products by European regulators may support subsequent relative effectiveness assessments by health technology assessment organizations.
Rick A. Vreman, A. D. de Ruijter, A. Zawada, G. Tafuri +9 more
2020Drug Discovery Today15 citations Open access
Semantic Scholar
A new anti-cancer drug in the market: Good news for investors or for patients?
G. Apolone, G. Tafuri, F. Trotta, S. Garattini
2008European Journal of Cancer15 citations
Semantic Scholar
Access and pricing of medicines for patients with rare diseases in the European Union: an industry perspective
G. Tafuri, A. Bracco, J. Grueger
2021Expert review of pharmacoeconomics & outcomes research11 citations
Semantic Scholar
Therapeutic indications in oncology: emerging features and regulatory dynamics.
G. Tafuri, H. Leufkens, R. Laing, F. Trotta
2010European Journal of Cancer10 citations Open access
Semantic Scholar
National and International Differences in the Prices of Branded and Unbranded Medicines
G. Tafuri, A. Creese, V. Reggi
20045 citations
Semantic Scholar
How Do Drug Regulatory Bodies Deal With Potential Innovative Therapies?
M. Tutone, F. Villa, A. Addis, F. Trotta +1 more
2020Therapeutic Innovation and Regulatory Science4 citations
Semantic Scholar
Comparing safety information of biosimilars with their originators: a cross‐sectional analysis of European risk management plans
Leroy R A Lepelaars, F. Renda, L. Pani, G. Pimpinella +5 more
2018British Journal of Clinical Pharmacology4 citations Open access
Semantic Scholar
Information needs on precision medicine: a survey of Italian health care professionals.
A. Addis, F. Trotta, G. Tafuri, L. de Fiore
2018Annali dell'Istituto Superiore di Sanità4 citations Open access
Semantic Scholar
Exploring the regulatory decision-making process for medicines
G. Tafuri
20134 citations
Semantic Scholar
Access and pricing of medicines for patients with rare diseases in the European Union: an industry perspective. A 2025 update
G. Tafuri, A. Bracco, J. Grueger
2025Expert review of pharmacoeconomics & outcomes research2 citations
Semantic Scholar
How Do Drug Regulatory Bodies Deal With Potential Innovative Therapies?
M. Tutone, F. Villa, A. Addis, F. Trotta +1 more
2019Therapeutic Innovation and Regulatory Science2 citations
Semantic Scholar
[Innovative medicinal products: the new criteria of the Italian Medicines Agency.]
F. Mammarella, G. Tafuri
2018Recenti progressi in medicina2 citations
Semantic Scholar
Baskin as a Lever for School Inclusion in Secondary School: An Experimental Study Between Sport, Citizenship and Relational Well-Being
Gianluca Gravino, D. Di Palma, Maria Giovanna Tafuri, Giovanna Scala +2 more
2026Education sciences1 citations Open access
Semantic Scholar
Physical Activity, Cognitive Function, and Learning Processes: The Role of Environmental Context
F. Latino, G. Tafuri, Giulia Amato, Generoso Romano
2025Behavioral Science1 citations
Semantic Scholar
The fourth edition of the European Network for Health Technology Assessment Forum: highlights and outcomes
G. Tafuri, C. Bélorgey, C. Favaretti, Edith Frénoy +16 more
2020International Journal of Technology Assessment in Health Care1 citations
Semantic Scholar
Effects of Individualised Nutrition on Performance and Athlete Triad Risk
Fabiola Palmiero, G. Tafuri, Giulia Amato, Generoso Romano
2026Physical Education Theory and Methodology0 citations Open access
Semantic Scholar
Sustainability in Youth Sport Performance: A Study on Anthropometry and Motor Skills in Women's Tennis
Fabio Scamardella, G. Tafuri, Alessandro Persico, Marko Joksimović +1 more
2026RIVISTA DI STUDI SULLA SOSTENIBILITA0 citations
Semantic Scholar
Participatory methodologies for evaluating and improving Learning City policies
Fabiola Palmiero, G. Tafuri, Generoso Romano
2026Form@re : Open Journal per la Formazione in Rete0 citations Open access
Semantic Scholar
Functional Joint Mobility in Young Athletes Practicing Bocce Raffa: Implications for the Performance Model
Fabio Scamardella, F. Latino, Generoso Romano, G. Tafuri +2 more
2026Physical Education Theory and Methodology0 citations Open access
Semantic Scholar
Narrazione, cooperazione e life design nella scuola media: percorsi per promuovere Progetto di Vita, benessere e inclusione
D. Di Palma, Giovanna Scala, Gianluca Gravino, G. Tafuri
2025EDUCATION SCIENCES AND SOCIETY0 citations
Semantic Scholar
[Establishing the value of new drugs in Italy.]
F. Villa, C. Jommi, G. Altamura, S. Antignani +5 more
2020Recenti progressi in medicina0 citations
Semantic Scholar
How aligned are the perspectives of European Union regulators and the Health Technology Assessment (HTA) bodies? A comparative analysis of regulatory-HTA parallel scientific advice
G. Tafuri, M. Pagnini, Jane Moseley, M. Massari +12 more
20160 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

F. Trotta×13
Invite
F. Trotta — researcher profile on SciRah
F. Villa×5
Invite
F. Villa — researcher profile on SciRah
Generoso Romano×5
Invite
Generoso Romano — researcher profile on SciRah
S. Garattini×4
Invite
S. Garattini — researcher profile on SciRah

×4

Invite

Niklas Hedberg — researcher profile on SciRah

Invite

H. Leufkens — researcher profile on SciRah

Invite

A. Addis — researcher profile on SciRah

Invite

R. Laing — researcher profile on SciRah

Jane Moseley×3

Invite

Jane Moseley — researcher profile on SciRah

Invite

M. Massari — researcher profile on SciRah

Invite

F. Pétavy — researcher profile on SciRah

Invite

E. Gajraj — researcher profile on SciRah